Equities Analysts Set Expectations for BNTC FY2026 Earnings

Benitec Biopharma Limited (NASDAQ:BNTC) – Equities research analysts at HC Wainwright upped their FY2026 earnings estimates for shares of Benitec Biopharma in a research note issued to investors on Tuesday, May 26th. HC Wainwright analyst R. Selvaraju now forecasts that the biotechnology company will earn ($0.96) per share for the year, up from their previous forecast of ($0.97). HC Wainwright has a “Buy” rating and a $32.00 price objective on the stock. The consensus estimate for Benitec Biopharma’s current full-year earnings is ($1.06) per share. HC Wainwright also issued estimates for Benitec Biopharma’s Q4 2026 earnings at ($0.25) EPS, Q1 2027 earnings at ($0.28) EPS, Q2 2027 earnings at ($0.31) EPS, Q3 2027 earnings at ($0.33) EPS, Q4 2027 earnings at ($0.37) EPS and FY2027 earnings at ($1.29) EPS.

BNTC has been the topic of a number of other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Benitec Biopharma in a report on Monday, April 20th. TD Cowen reissued a “buy” rating on shares of Benitec Biopharma in a report on Monday, March 9th. Evercore started coverage on shares of Benitec Biopharma in a report on Tuesday, May 12th. They issued an “outperform” rating and a $25.00 price target on the stock. Finally, Wall Street Zen raised shares of Benitec Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $27.00.

Benitec Biopharma Price Performance

Shares of NASDAQ:BNTC opened at $11.60 on Thursday. The company’s fifty day moving average price is $11.74 and its 200-day moving average price is $12.04. The firm has a market capitalization of $398.46 million, a price-to-earnings ratio of -10.18 and a beta of 0.28. Benitec Biopharma has a one year low of $9.85 and a one year high of $17.15.

Benitec Biopharma (NASDAQ:BNTC) last issued its quarterly earnings results on Thursday, May 14th. The biotechnology company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.03.

Hedge Funds Weigh In On Benitec Biopharma

Several institutional investors and hedge funds have recently made changes to their positions in BNTC. Goldman Sachs Group Inc. bought a new position in shares of Benitec Biopharma during the 1st quarter valued at $597,000. Geode Capital Management LLC grew its holdings in shares of Benitec Biopharma by 77.6% during the 2nd quarter. Geode Capital Management LLC now owns 415,211 shares of the biotechnology company’s stock valued at $4,859,000 after purchasing an additional 181,391 shares during the last quarter. JPMorgan Chase & Co. bought a new position in shares of Benitec Biopharma during the 2nd quarter valued at $80,000. Rhumbline Advisers grew its holdings in shares of Benitec Biopharma by 11,114.0% during the 2nd quarter. Rhumbline Advisers now owns 20,858 shares of the biotechnology company’s stock valued at $244,000 after purchasing an additional 20,672 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in shares of Benitec Biopharma during the 2nd quarter valued at $127,000. Institutional investors own 52.19% of the company’s stock.

Benitec Biopharma Company Profile

Benitec Biopharma Ltd (NASDAQ: BNTC) is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company’s proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration.

Benitec’s lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions.